Jean N. DaSilva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jean N. DaSilva has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
Rob S. Beanlands
Cardiac PET Centre, Department of Medicine (Division of Cardiology), University of Ottawa Heart Institute, Ottawa, ON, Canada
10 shared publications- Robert A. Dekemp
Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, ON, Canada (R.A.d.).
8 shared publications - Robert S. B. Beanlands
Division of Cardiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
7 shared publications Tayebeh Hadizad
Cardiac PET Centre, Department of Medicine (Division of Cardiology), University of Ottawa Heart Institute, Ottawa, ON, Canada
7 shared publicationsRobert A. Dekemp
National Cardiac PET Centre, University of Ottawa Heart Institute, 40 Ruskin St., Ottawa, ON, K1Y 4W7, Canada
6 shared publicationsBasma Ismail
Cardiac PET Centre, Department of Medicine (Division of Cardiology), University of Ottawa Heart Institute, Ottawa, ON, Canada
5 shared publications
Latest Publications
- Open Access
- 29 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3999
Transient Increase in AT1R Expression at the Myocardial Infarct Site Is Associated with Early Fibrotic Remodeling in Infarcted Rat Heart
Myocardial infarction initiates complex remodeling processes involving the renin–angiotensin system, through activation of the angiotensin II type 1 receptor (AT1R). This study correlated AT1R expression with fibrosis and cardiac function in the heart and kidneys following cardiac ischemic injury in animal models. Male Sprague-Dawley rats underwent Sham surgery, Ischemia/Reperfusion (I/R, 20-min ligation) or Permanent Ligation (PL) of the left anterior descending artery. Cardiac function was assessed by echocardiography. AT1R expression was measured in the heart (infarct and remote areas) and kidneys (cortex, medulla) via [125Iodine]Sarcosine1-Isoleucine8-Angiotensin II autoradiography. Collagen deposition was evaluated through picrosirius red staining. Left ventricular (LV) ejection fraction declined in PL models but remained stable following I/R. Post-I/R, a transient increase in cardiac AT1R (day-3 to week-5) correlated with an increase in collagen, whereas after PL, elevations persisted through week-12. Infarct areas consistently displayed higher AT1R and collagen than remote areas. Renal AT1R and collagen levels were unchanged across groups. In analyses with pooled animals, cardiac AT1R expression correlated with collagen and inversely correlated with LV Fractional Shortening (LVFS), whereas LVFS inversely correlated with collagen deposition. These findings suggest that cardiac AT1R levels may serve as a target of cardiac remodeling, while changes in renal AT1R appear less pronounced.
- 29 April 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (9) , 3999
Open AccessTransient Increase in AT1R Expression at the Myocardial Infarct Site Is Associated with Early Fibrotic Remodeling in Infarcted Rat Heart
Myocardial infarction initiates complex remodeling processes involving the renin–angiotensin system, through activation of the angiotensin II type 1 receptor (AT1R). This study correlated AT1R expression with fibrosis and cardiac function in the heart and kidneys following cardiac ischemic injury in animal models. Male Sprague-Dawley rats underwent Sham surgery, Ischemia/Reperfusion (I/R, 20-min ligation) or Permanent Ligation (PL) of the left anterior descending artery. Cardiac function was assessed by echocardiography. AT1R expression was measured in the heart (infarct and remote areas) and kidneys (cortex, medulla) via [125Iodine]Sarcosine1-Isoleucine8-Angiotensin II autoradiography. Collagen deposition was evaluated through picrosirius red staining. Left ventricular (LV) ejection fraction declined in PL models but remained stable following I/R. Post-I/R, a transient increase in cardiac AT1R (day-3 to week-5) correlated with an increase in collagen, whereas after PL, elevations persisted through week-12. Infarct areas consistently displayed higher AT1R and collagen than remote areas. Renal AT1R and collagen levels were unchanged across groups. In analyses with pooled animals, cardiac AT1R expression correlated with collagen and inversely correlated with LV Fractional Shortening (LVFS), whereas LVFS inversely correlated with collagen deposition. These findings suggest that cardiac AT1R levels may serve as a target of cardiac remodeling, while changes in renal AT1R appear less pronounced.
- Open Access
A Reliable Production System of Large Quantities of [13N]Ammonia for Multiple Human Injections
[13N]Ammonia is one of the most commonly used Positron Emission Tomography (PET) radiotracers in humans to assess myocardial perfusion and measure myocardial blood flow. Here, we report a reliable semi-automated process to manufacture large quantities of [13N]ammonia in high purity by proton-irradiation of a 10 mM aqueous ethanol solution using an in-target process under aseptic conditions. Our simplified production system is based on two syringe driver units and an in-line anion-exchange purification for up to three consecutive productions of ~30 GBq (~800 mCi) (radiochemical yield = 69 ± 3% n.d.c) per day. The total manufacturing time, including purification, sterile filtration, reformulation, and quality control (QC) analyses performed before batch release, is approximately 11 min from the End of Bombardment (EOB). The drug product complies with FDA/USP specifications and is supplied in a multidose vial allowing for two doses per patient, two patients per batch (4 doses/batch) on two separate PET scanners simultaneously. After four years of use, this production system has proved to be easy to operate and maintain at low costs. Over the last four years, more than 1000 patients have been imaged using this simplified procedure, demonstrating its reliability for the routine production of large quantities of current Good Manufacturing Practices (cGMP)-compliant [13N]ammonia for human use.
Open AccessA Reliable Production System of Large Quantities of [13N]Ammonia for Multiple Human Injections
[13N]Ammonia is one of the most commonly used Positron Emission Tomography (PET) radiotracers in humans to assess myocardial perfusion and measure myocardial blood flow. Here, we report a reliable semi-automated process to manufacture large quantities of [13N]ammonia in high purity by proton-irradiation of a 10 mM aqueous ethanol solution using an in-target process under aseptic conditions. Our simplified production system is based on two syringe driver units and an in-line anion-exchange purification for up to three consecutive productions of ~30 GBq (~800 mCi) (radiochemical yield = 69 ± 3% n.d.c) per day. The total manufacturing time, including purification, sterile filtration, reformulation, and quality control (QC) analyses performed before batch release, is approximately 11 min from the End of Bombardment (EOB). The drug product complies with FDA/USP specifications and is supplied in a multidose vial allowing for two doses per patient, two patients per batch (4 doses/batch) on two separate PET scanners simultaneously. After four years of use, this production system has proved to be easy to operate and maintain at low costs. Over the last four years, more than 1000 patients have been imaged using this simplified procedure, demonstrating its reliability for the routine production of large quantities of current Good Manufacturing Practices (cGMP)-compliant [13N]ammonia for human use.
- Open Access
- 1 February 2023
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 66 (3) , 73-85
[18F]Fluoropyridine‐losartan: A new approach toward human Positron Emission Tomography imaging of Angiotensin II Type 1 receptors
Angiotensin II type 1 receptors (AT1R) blocker losartan is used in patients with renal and cardiovascular diseases. [18F]fluoropyridine‐losartan has shown favorable binding profile for quantitative renal PET imaging of AT1R with selective binding in rats and pigs, low interference of radiometabolites and appropriate dosimetry for clinical translation. A new approach was developed to produce [18F]fluoropyridine‐losartan in very high molar activity. Automated radiosynthesis was performed in a three‐step, two‐pot, and two‐HPLC‐purification procedure within 2 h. Pure [18F]FPyKYNE was obtained by radiofluorination of NO2PyKYNE and silica‐gel‐HPLC purification (40 ± 9%), preventing the formation of nitropyridine‐losartan in the second step. Conjugation with trityl‐losartan azide via click chemistry, followed by acid hydrolysis, C18‐HPLC purification and reformulation provided [18F]fluoropyridine‐losartan in 11 ± 2% (decay‐corrected from [18F]fluoride, EOB). Using tris[(1‐(3‐hydroxypropyl)‐1H‐1,2,3‐triazol‐4‐yl)methyl]‐amine (THPTA) as a Cu(I)‐stabilizing agent for coupling [18F]FPyKYNE to the unprotected losartan azide afforded [18F]fluoropyridine‐losartan in similar yields (11 ± 3%, decay‐corrected from [18F]fluoride, EOB). Reverse‐phase HPLC was optimized by reducing the pH of the mobile phase to achieve complete purification and high molar activities (467 ± 60 GBq/μmol). The use of radioprotectants prevented tracer radiolysis for 10 h (RCP > 99%). The product passed the quality control testing. This reproducible automated radiosynthesis process will allow in vivo PET imaging of AT1R expression in several diseases.
- 1 February 2023
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 66 (3) , 73-85
Open Access[18F]Fluoropyridine‐losartan: A new approach toward human Positron Emission Tomography imaging of Angiotensin II Type 1 receptors
Angiotensin II type 1 receptors (AT1R) blocker losartan is used in patients with renal and cardiovascular diseases. [18F]fluoropyridine‐losartan has shown favorable binding profile for quantitative renal PET imaging of AT1R with selective binding in rats and pigs, low interference of radiometabolites and appropriate dosimetry for clinical translation. A new approach was developed to produce [18F]fluoropyridine‐losartan in very high molar activity. Automated radiosynthesis was performed in a three‐step, two‐pot, and two‐HPLC‐purification procedure within 2 h. Pure [18F]FPyKYNE was obtained by radiofluorination of NO2PyKYNE and silica‐gel‐HPLC purification (40 ± 9%), preventing the formation of nitropyridine‐losartan in the second step. Conjugation with trityl‐losartan azide via click chemistry, followed by acid hydrolysis, C18‐HPLC purification and reformulation provided [18F]fluoropyridine‐losartan in 11 ± 2% (decay‐corrected from [18F]fluoride, EOB). Using tris[(1‐(3‐hydroxypropyl)‐1H‐1,2,3‐triazol‐4‐yl)methyl]‐amine (THPTA) as a Cu(I)‐stabilizing agent for coupling [18F]FPyKYNE to the unprotected losartan azide afforded [18F]fluoropyridine‐losartan in similar yields (11 ± 3%, decay‐corrected from [18F]fluoride, EOB). Reverse‐phase HPLC was optimized by reducing the pH of the mobile phase to achieve complete purification and high molar activities (467 ± 60 GBq/μmol). The use of radioprotectants prevented tracer radiolysis for 10 h (RCP > 99%). The product passed the quality control testing. This reproducible automated radiosynthesis process will allow in vivo PET imaging of AT1R expression in several diseases.
- 1 November 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 102-103, 34-44
Novel O-[11C]-methylated derivatives of the neprilysin inhibitor sacubitril: Radiosynthesis, autoradiography and plasma stability evaluation
- 1 November 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 102-103, 34-44
Novel O-[11C]-methylated derivatives of the neprilysin inhibitor sacubitril: Radiosynthesis, autoradiography and plasma stability evaluation
- 1 May 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 41-49
Evaluation of the high affinity [18F]fluoropyridine-candesartan in rats for PET imaging of renal AT1 receptors
- 1 May 2021
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 96-97, 41-49
Evaluation of the high affinity [18F]fluoropyridine-candesartan in rats for PET imaging of renal AT1 receptors
- Open Access
- 18 March 2021
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 6 (1) , 1-19
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Conclusion: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
- 18 March 2021
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 6 (1) , 1-19
Open AccessHighlight selection of radiochemistry and radiopharmacy developments by editorial board
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results: This commentary of highlights has resulted in 23 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Conclusion: Trends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
- Open Access
- 28 January 2021
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 6 (1) , 1-13
Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020)
BackgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to describe trends in the field.ResultsThis commentary of highlights has resulted in 19 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.ConclusionTrends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
- 28 January 2021
- Published by Springer Nature in EJNMMI Radiopharmacy and Chemistry
- Vol. 6 (1) , 1-13
Open AccessHighlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020)
BackgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to describe trends in the field.ResultsThis commentary of highlights has resulted in 19 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.ConclusionTrends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
- 20 October 2020
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 64 (3) , 120-128
Development of a novel [18F]fluorobenzyl derivative of the AT1 receptor antagonist Candesartan
Candesartan is a clinically approved angiotensin II type 1 receptor (AT1R)‐blocker that selectively binds AT1Rs in high affinity. We report here the radiosynthesis and automation of the novel [18F]fluorobenzyl derivative of Candesartan using the Sonogashira cross‐coupling reaction. [18F]Fluorobenzyl‐Candesartan ([18F]7) was developed from 4‐[18F]fluoroiodobenzene ([18F]FIB) that was conjugated with alkyne‐trityl‐candesartan with the assistance of a Pd (PPh3)4/CuI catalyst followed by acid deprotection. The three‐step two‐reactor 2‐HPLC purification process was automated resulting in >90% pure [18F]7 in a RCY of 4.6 ± 1.1% (decay corrected from EOB) and molar activities of 1,406‐5,513 GBq/mmol. [18F]FIB was reproducibly obtained by direct radiofluorination of the mono‐iodinated triphenylsulfonium salt in the presence of K222/K2CO3 in an ~30% yield (decay‐corrected). [18F]7 was stable (>97%) up to 4 h in solution and up to 1 h in rat plasma at 37°C. However, the use of Sonogashira cross‐coupling reaction to produce [18F]7 in high yields and molar activities was found to be challenging for routine use in radiochemistry labs.
- 20 October 2020
- Published by Wiley in Journal of Labelled Compounds and Radiopharmaceuticals
- Vol. 64 (3) , 120-128
Development of a novel [18F]fluorobenzyl derivative of the AT1 receptor antagonist Candesartan
Candesartan is a clinically approved angiotensin II type 1 receptor (AT1R)‐blocker that selectively binds AT1Rs in high affinity. We report here the radiosynthesis and automation of the novel [18F]fluorobenzyl derivative of Candesartan using the Sonogashira cross‐coupling reaction. [18F]Fluorobenzyl‐Candesartan ([18F]7) was developed from 4‐[18F]fluoroiodobenzene ([18F]FIB) that was conjugated with alkyne‐trityl‐candesartan with the assistance of a Pd (PPh3)4/CuI catalyst followed by acid deprotection. The three‐step two‐reactor 2‐HPLC purification process was automated resulting in >90% pure [18F]7 in a RCY of 4.6 ± 1.1% (decay corrected from EOB) and molar activities of 1,406‐5,513 GBq/mmol. [18F]FIB was reproducibly obtained by direct radiofluorination of the mono‐iodinated triphenylsulfonium salt in the presence of K222/K2CO3 in an ~30% yield (decay‐corrected). [18F]7 was stable (>97%) up to 4 h in solution and up to 1 h in rat plasma at 37°C. However, the use of Sonogashira cross‐coupling reaction to produce [18F]7 in high yields and molar activities was found to be challenging for routine use in radiochemistry labs.
- Open Access
- 16 August 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (33) , 20960-20966
Synthesis of a 11C-Isotopologue of the B-Raf-Selective Inhibitor Encorafenib Using In-Loop [11C]CO2 Fixation
The serine/threonine kinase B-Raf is an essential regulator of cellular growth, differentiation, and survival. B-Raf protein expression is elevated throughout melanoma progression, making it an attractive target for noninvasive imaging using positron–emission tomography. Encorafenib is a potent and highly selective inhibitor of B-Raf used in the clinical management of melanoma. In this study, the radiosynthesis of a 11C-isotopologue of encorafenib was developed using an in-loop [11C]CO2 fixation reaction. Optimization of reaction conditions reduced the formation of a radiolabeled side product and improved the isolated yields of [11C]encorafenib (14.5 ± 2.4% radiochemical yield). The process was fully automated using a commercial radiosynthesizer for the production of 6845 ± 888 MBq of [11C]encorafenib in high molar activity (177 ± 5 GBq μmol–1), in high radiochemical purity (99%), and in a formulation suitable for animal injection. An in vitro cellular binding experiment demonstrated saturable binding of the radiotracer to A375 melanoma cells.
- 16 August 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (33) , 20960-20966
Open AccessSynthesis of a 11C-Isotopologue of the B-Raf-Selective Inhibitor Encorafenib Using In-Loop [11C]CO2 Fixation
The serine/threonine kinase B-Raf is an essential regulator of cellular growth, differentiation, and survival. B-Raf protein expression is elevated throughout melanoma progression, making it an attractive target for noninvasive imaging using positron–emission tomography. Encorafenib is a potent and highly selective inhibitor of B-Raf used in the clinical management of melanoma. In this study, the radiosynthesis of a 11C-isotopologue of encorafenib was developed using an in-loop [11C]CO2 fixation reaction. Optimization of reaction conditions reduced the formation of a radiolabeled side product and improved the isolated yields of [11C]encorafenib (14.5 ± 2.4% radiochemical yield). The process was fully automated using a commercial radiosynthesizer for the production of 6845 ± 888 MBq of [11C]encorafenib in high molar activity (177 ± 5 GBq μmol–1), in high radiochemical purity (99%), and in a formulation suitable for animal injection. An in vitro cellular binding experiment demonstrated saturable binding of the radiotracer to A375 melanoma cells.
- 3 August 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (32) , 20353-20362
Synthesis of the Novel AT1 Receptor Tracer [18F]Fluoropyridine–Candesartan via Click Chemistry
A novel 7-((4-(3-((2-[18F]fluoropyridin-3-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)methyl)-1H-benzo[d]imidazole derivative of the angiotensin II type-1 receptor (AT1R) blocker candesartan, [18F]fluoropyridine–candesartan, was synthesized via the copper-catalyzed azide–alkyne cycloaddition click reaction between 2-[18F]fluoro-3-(pent-4-yn-1-yloxy)pyridine ([18F]FPyKYNE) and the tetrazole-protected azido-candesartan derivative, followed by acid deprotection. This three-step, two-pot, and two-step purification synthesis was done within 2 h. The use of tris[(1-hydroxypropyl-1H-1,2,3-triazol-4-yl)methyl]amine (THPTA) as a Cu(I) stabilizing agent increased the overall radiochemical yield by 4-fold (10 ± 2%, n = 13) compared to the reaction without THPTA (2.4 ± 0.2%, n = 3; decay-corrected from 18F produced at the end-of-beam). Complete separation of [18F]FPyKYNE from its nitro precursor and [18F]fluoropyridine–candesartan from the deprotected azido-candesartan allowed for high molar activities (>380 GBq/μmol) of the tracer. The use of 0.1% trifluoroacetic acid in water for reformulation and the addition of sodium ascorbate to the final formulation (1.6 ± 0.2 GBq/mL, n = 3) prevented tracer radiolysis with >97% radiochemical purity for a period of up to 10 h after the end-of-synthesis. A significant reduction in the uptake (86 ± 3%, n = 8) of the tracer was observed ex vivo in rats (at 20 min postinjection) in the AT1R-rich kidney cortex following pretreatment with saturating doses of the AT1R antagonist candesartan or losartan. This specific binding to AT1R was confirmed in vitro in the rat renal cortex (autoradiography) by a reduction of 26 ± 5% (n = 12) with losartan coincubation (10 μM). These favorable binding properties support further studies to assess the potential of [18F]fluoropyridine–candesartan as a tracer for the positron emission tomography imaging of renal AT1R.
- 3 August 2020
- Published by American Chemical Society (ACS) in ACS Omega
- Vol. 5 (32) , 20353-20362
Synthesis of the Novel AT1 Receptor Tracer [18F]Fluoropyridine–Candesartan via Click Chemistry
A novel 7-((4-(3-((2-[18F]fluoropyridin-3-yl)oxy)propyl)-1H-1,2,3-triazol-1-yl)methyl)-1H-benzo[d]imidazole derivative of the angiotensin II type-1 receptor (AT1R) blocker candesartan, [18F]fluoropyridine–candesartan, was synthesized via the copper-catalyzed azide–alkyne cycloaddition click reaction between 2-[18F]fluoro-3-(pent-4-yn-1-yloxy)pyridine ([18F]FPyKYNE) and the tetrazole-protected azido-candesartan derivative, followed by acid deprotection. This three-step, two-pot, and two-step purification synthesis was done within 2 h. The use of tris[(1-hydroxypropyl-1H-1,2,3-triazol-4-yl)methyl]amine (THPTA) as a Cu(I) stabilizing agent increased the overall radiochemical yield by 4-fold (10 ± 2%, n = 13) compared to the reaction without THPTA (2.4 ± 0.2%, n = 3; decay-corrected from 18F produced at the end-of-beam). Complete separation of [18F]FPyKYNE from its nitro precursor and [18F]fluoropyridine–candesartan from the deprotected azido-candesartan allowed for high molar activities (>380 GBq/μmol) of the tracer. The use of 0.1% trifluoroacetic acid in water for reformulation and the addition of sodium ascorbate to the final formulation (1.6 ± 0.2 GBq/mL, n = 3) prevented tracer radiolysis with >97% radiochemical purity for a period of up to 10 h after the end-of-synthesis. A significant reduction in the uptake (86 ± 3%, n = 8) of the tracer was observed ex vivo in rats (at 20 min postinjection) in the AT1R-rich kidney cortex following pretreatment with saturating doses of the AT1R antagonist candesartan or losartan. This specific binding to AT1R was confirmed in vitro in the rat renal cortex (autoradiography) by a reduction of 26 ± 5% (n = 12) with losartan coincubation (10 μM). These favorable binding properties support further studies to assess the potential of [18F]fluoropyridine–candesartan as a tracer for the positron emission tomography imaging of renal AT1R.